NCT02557399 - DUAC® Early Onset Efficacy Study in Japanese Subjects | Biotech Hunter

Enrollment

350

Participants

Timeline

Start Date

October 7, 2015

Primary Completion Date

December 17, 2015

Study Completion Date

February 17, 2016

Conditions

Acne Vulgaris

Interventions

DRUG

Duac® fixed dose combination gel

Duac® fixed dose combination gel containing clindamycin phosphate 1.2% and benzoyl peroxide 3%.

DRUG

ADA 0.1% gel

ADA 0.1% gel containing 0.1% of adapalene.

DRUG

CLDM 1% gel

CLDM 1% gel containing clindamycin phosphate 1.2% (1% as clindamycin).

Trial Locations (15)

453-0054

GSK Investigational Site, Aichi

464-0821

GSK Investigational Site, Aichi

468-0011

GSK Investigational Site, Aichi

272-0143

GSK Investigational Site, Chiba

273-0046

GSK Investigational Site, Chiba

221-0825

GSK Investigational Site, Kanagawa

242-0007

GSK Investigational Site, Kanagawa

560-0824

GSK Investigational Site, Osaka

572-0838

GSK Investigational Site, Osaka

580-0032

GSK Investigational Site, Osaka

593-8324

GSK Investigational Site, Osaka

333-0055

GSK Investigational Site, Saitama

133-0057

GSK Investigational Site, Tokyo

143-0023

GSK Investigational Site, Tokyo

169-0075

GSK Investigational Site, Tokyo